Nexien Biopharma, INC.
SEC CIK 1625288 · NXEN · last insider filing 2024-05-28
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Greenberg Richard S | Director · EVP and Chairman | filed 2017 - 2024 |
| Snider Lindy | Director | filed 2018 - 2021 |
| Friedland Jeffrey | Director · Chief Executive Officer | filed 2017 - 2019 |
| Bankier Alain D | Director · Executive Chairman | filed 2017 - 2019 |
| Wasyl Alexander Michael | Director · Chief Executive Officer | filed 2018 - 2018 |
| Clark Courtney Lynne | Director | filed 2018 - 2018 |
| Heiden Ivo | Director · CEO and Chairman | filed 2016 - 2016 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Wasoff Evan L | Chief Financial Officer | filed 2017 - 2024 |
| Goldfarb Robert I | Chief Operating Officer | filed 2017 - 2023 |
| Manganella Frank J | VP Corporate Development | filed 2018 - 2018 |
| Reeh Jeremy Robert | VP Translational Research | filed 2018 - 2018 |
| Aceto Joseph F | VP Legal & IP Counsel | filed 2018 - 2018 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.